INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,893,613 | +474.4% | 1,019,073 | +242.6% | 0.00% | +300.0% |
| Q2 2023 | $3,289,465 | -67.9% | 297,420 | -61.0% | 0.00% | -50.0% |
| Q1 2023 | $10,247,546 | +50.6% | 763,034 | +38.7% | 0.00% | 0.0% |
| Q4 2022 | $6,806,456 | +21.2% | 550,239 | +36.7% | 0.00% | +100.0% |
| Q3 2022 | $5,614,000 | +10.6% | 402,466 | +9.5% | 0.00% | 0.0% |
| Q2 2022 | $5,076,000 | -34.9% | 367,535 | -23.3% | 0.00% | -50.0% |
| Q1 2022 | $7,792,000 | +10.2% | 478,923 | +10.4% | 0.00% | +100.0% |
| Q4 2021 | $7,068,000 | +59.4% | 433,967 | +45.4% | 0.00% | 0.0% |
| Q3 2021 | $4,433,000 | -44.2% | 298,492 | -25.0% | 0.00% | -50.0% |
| Q2 2021 | $7,943,000 | -30.6% | 397,763 | -19.8% | 0.00% | -33.3% |
| Q1 2021 | $11,445,000 | -53.7% | 495,877 | -50.5% | 0.00% | -50.0% |
| Q4 2020 | $24,734,000 | -10.7% | 1,001,382 | +49.8% | 0.01% | -25.0% |
| Q3 2020 | $27,708,000 | +38.1% | 668,303 | +59.6% | 0.01% | +33.3% |
| Q2 2020 | $20,065,000 | +23.9% | 418,821 | +62.8% | 0.01% | 0.0% |
| Q1 2020 | $16,193,000 | -14.7% | 257,197 | +68.0% | 0.01% | +20.0% |
| Q4 2019 | $18,977,000 | -7.2% | 153,139 | -50.3% | 0.01% | -16.7% |
| Q3 2019 | $20,457,000 | -7.3% | 308,262 | +11.1% | 0.01% | 0.0% |
| Q2 2019 | $22,079,000 | -56.0% | 277,482 | -38.1% | 0.01% | -62.5% |
| Q1 2019 | $50,182,000 | +56.8% | 448,613 | +41.2% | 0.02% | +60.0% |
| Q4 2018 | $32,012,000 | +13.1% | 317,613 | +41.8% | 0.01% | +42.9% |
| Q3 2018 | $28,305,000 | +77.2% | 223,998 | +17.7% | 0.01% | +75.0% |
| Q2 2018 | $15,975,000 | +83.5% | 190,384 | +34.6% | 0.00% | +100.0% |
| Q1 2018 | $8,705,000 | -19.4% | 141,487 | -23.5% | 0.00% | -33.3% |
| Q4 2017 | $10,799,000 | +44.6% | 184,846 | +43.7% | 0.00% | +50.0% |
| Q3 2017 | $7,468,000 | -55.7% | 128,669 | -7.6% | 0.00% | -50.0% |
| Q2 2017 | $16,859,000 | +14.0% | 139,253 | +6.5% | 0.00% | 0.0% |
| Q1 2017 | $14,793,000 | +164.8% | 130,792 | +154.4% | 0.00% | +300.0% |
| Q4 2016 | $5,586,000 | -36.1% | 51,412 | -3.2% | 0.00% | -50.0% |
| Q3 2016 | $8,745,000 | -3.2% | 53,134 | -16.1% | 0.00% | -33.3% |
| Q2 2016 | $9,038,000 | +127.4% | 63,339 | +104.8% | 0.00% | +200.0% |
| Q1 2016 | $3,974,000 | -78.0% | 30,934 | -74.4% | 0.00% | -83.3% |
| Q4 2015 | $18,063,000 | +81.4% | 120,946 | +101.4% | 0.01% | +50.0% |
| Q3 2015 | $9,959,000 | -25.9% | 60,045 | +7.8% | 0.00% | 0.0% |
| Q2 2015 | $13,442,000 | -75.1% | 55,690 | -70.9% | 0.00% | -77.8% |
| Q1 2015 | $53,957,000 | +221.0% | 191,323 | +77.5% | 0.02% | +200.0% |
| Q4 2014 | $16,810,000 | -49.5% | 107,759 | -23.4% | 0.01% | -45.5% |
| Q3 2014 | $33,292,000 | -54.5% | 140,655 | -54.5% | 0.01% | -52.2% |
| Q2 2014 | $73,213,000 | +49.9% | 309,399 | +109.0% | 0.02% | +43.8% |
| Q1 2014 | $48,833,000 | – | 148,073 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |